✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
The combination of ceftazidime or imipenem with amikacin appears appropriate for the treatment of newborns with Serratia infection.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:As smaller babies survive in neonatal intensive care units, late-onset septicemia with unusual pathogens appears.
📊
Key Findings & Data:Between 1 January and 31 December 1998, in Hacettepe University Ihsan Dogramaci Children's Hospital Neonatal Intensive Care Unit, seven infants had S. marcescens isolates.
💡
Conclusion & Impact:The combination of ceftazidime or imipenem with amikacin appears appropriate for the treatment of newborns with Serratia infection.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
As smaller babies survive in neonatal intensive care units, late-onset septicemia with unusual pathogens appears. Between 1 January and 31 December 1998, in Hacettepe University Ihsan Dogramaci Children's Hospital Neonatal Intensive Care Unit, seven infants had S. marcescens isolates. Four babies had septicemia with the microorganism. The case fatality rate was 50 percent in infants with S. marcescens septicemia. The combination of ceftazidime or imipenem with amikacin appears appropriate for the treatment of newborns with Serratia infection.
🔖
Cite This Article
YİĞİT, Ş., TEKİNALP, G., ERDEM, G., YURDAKÖK, M., ORAN, O., GÜR, D., AYGÜN, C. (2022). Serratia marcescens: An emerging microorganism in the neonatal intensive care unit. Turkish Journal of Pediatrics, Cilt: 42 - Sayı: 3, 219–222. https://ajindex.com/articles/613369